12 marzo 2015
Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response. In addition, the ‘turbocharged’ clotting factor protein eliminated pre-existing antibodies that often weaken conventional treatments for people with hemophilia
http://feeds.sciencedaily.com/~r/sciencedaily/~3/Cb3OGgjapPw/150312112256.htm
